NEW YORK CITY – APRIL 28, 2022 – Informa Pharma Intelligence, the global business intelligence provider for the biopharma industry, and The American Society of Gene & Cell Therapy (ASGCT), today announced the launch of the Gene, Cell & RNA Therapy Landscape Q1 2022 Quarterly Data Report. The Q1 2022 report assesses industry trends by examining approved gene, cell and RNA therapies, the pharmaceutical pipeline by company, most targeted therapeutic areas, and an overview of recent dealmaking and start-up funding.
Notable findings from the first quarterly report of the year include:
“Since we started putting these quarterly reports together in Q1 2021, we have seen the gene therapy pipeline steadily increase. Oncology and rare disease remain the most targeted therapeutic areas, and we continue to see a strong pipeline for CAR-T cell therapies for cancer indications,” said Ly Nguyen-Jatkoe, PhD, Executive Director, Americas, Informa Pharma Intelligence. “Rare diseases continue to be a focus for RNA therapies.”
“The continued approvals of gene and cell therapies has turned into one of the brightest spots in releasing this report each quarter,” said David Barrett, JD, CEO, the American Society of Gene & Cell Therapy (ASGCT). “With the approval of Carvykti in Q1 2022 and the ever-expanding pipeline, we’re exceptionally optimistic about the future of the field.”
All pipeline and trial insights were compiled using data from Pharma Intelligence’s Pharmaprojects™, and Trialtrove™, part of Citeline, which has been tracking global drug development since 1980. Deal, financing and catalyst data were derived from Biomedtracker™. For more information, or to view the current and past reports, visit Informa Pharma Intelligence or contact firstname.lastname@example.org.
About The American Society of Gene & Cell Therapy (ASGCT)
The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization for scientists, physicians, patient advocates and other professionals with interest in gene and cell therapy.
Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products — Datamonitor Healthcare™, Sitetrove™, Trialtrove™, Pharmaprojects™, Biomedtracker™, Scrip™, Pink Sheet™ and In Vivo™ — to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 400 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information, visit pharmaintelligence.informa.com
Diffusion PR for Informa Pharma Intelligence
Alex Wendland for The American Society of Gene & Cell Therapy (ASGCT)
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: